Daiichi Sankyo (OTCMKTS:DSNKY) Shares Gap Down – Here’s Why

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) gapped down before the market opened on Friday . The stock had previously closed at $17.79, but opened at $17.17. Daiichi Sankyo shares last traded at $17.17, with a volume of 1,186 shares.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on DSNKY. Jefferies Financial Group cut Daiichi Sankyo from a “buy” rating to a “hold” rating in a research note on Thursday, July 30th. Zacks Research lowered Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a research report on Monday, August 3rd. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Daiichi Sankyo presently has an average rating of “Reduce”.

Daiichi Sankyo Trading Down 1.7%

The company has a current ratio of 2.42, a quick ratio of 1.64 and a debt-to-equity ratio of 0.18. The firm has a market capitalization of $32.06 billion, a price-to-earnings ratio of 20.01, a P/E/G ratio of 3.43 and a beta of -0.18. The firm’s 50-day moving average is $16.66 and its 200 day moving average is $17.46.

Daiichi Sankyo (OTCMKTS:DSNKY) last announced its quarterly earnings results on Friday, July 31st. The company reported $0.24 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.25 by ($0.01). The business had revenue of $3.61 billion during the quarter, compared to analyst estimates of $3.32 billion. Daiichi Sankyo had a net margin of 10.92% and a return on equity of 14.22%. Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS. On average, equities analysts predict that Daiichi Sankyo Co., Ltd. – Sponsored ADR will post 0.87 earnings per share for the current fiscal year.

Daiichi Sankyo Company Profile

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody?drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.